Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + bevacizumab + XELOX as first-line therapy for MSS metastatic colorectal cancer
ChiCTR2600117932Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in colorectal cancer (CRC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: 1-year progression-free survival (PFS) rate. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2600117932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117932.